Beyond Meat's stock fell below $1, faces Nasdaq delisting, and has pivoted away from meat entirely after $14B peak valuation

Beyond Meat, the company that single-handedly created the plant-based meat category in mainstream consciousness, received a Nasdaq deficiency notice on March 4, 2026, after its stock traded below $1 for 30 consecutive business days. The company has 180 days — until August 31, 2026 — to regain compliance. Its shares have fallen approximately 76% in the past 12 months, and the market cap has collapsed from a peak of $14 billion after its 2019 IPO to less than $350 million. Annual revenue declined from $464 million in 2021 to $273.5 million, approaching 2019 levels. Q3 2025 revenue fell 13.3% year-over-year. The company's response has been to retreat from its core identity. Beyond Meat dropped 'Meat' from its name and launched 'Beyond Immense,' a functional protein beverage that has nothing to do with meat alternatives. This pivot signals that the company's own leadership no longer believes the plant-based meat analogue market can sustain a publicly traded company. For the broader industry, this is catastrophic: Beyond was the proof-of-concept that plant-based meat could be a venture-scale business. Its failure to retain customers — with 46% of US buyers citing taste dissatisfaction and declining to make repeat purchases — validated the criticism that plant-based meat analogues were a curiosity, not a replacement product. The structural problem is that Beyond Meat built a business on the assumption that initial consumer trial would convert to habitual purchasing, the way any CPG brand operates. But plant-based meat occupies an uncanny valley: it is marketed as a substitute for animal meat, which sets the expectation of identical taste and texture, but it consistently falls short on juiciness (62% less than animal meat in sensory panels), mouthfeel, and flavor. Consumers who try it once and find it lacking do not return. Meanwhile, the 'ultra-processed' backlash has turned health-conscious consumers — the very demographic most likely to buy plant-based — against products with long ingredient lists featuring methylcellulose and soy protein isolate. Beyond cannot win on taste against real meat or on health perception against whole foods, and now it cannot even sustain its stock price.